by Inhaled antibiotics are drugs that are administered through inhalation to treat or prevent various lung infections. They are mainly used for treating chronic respiratory diseases such as cystic fibrosis, non-cystic fibrosis bronchiectasis, and lung infections in immunocompromised patients. Some commonly used inhaled antibiotics include amikacin, aztreonam, ciprofloxacin, colistimethate, gentamicin, levofloxacin, and tobramycin. Inhaled antibiotics provide an effective alternative to intravenous and oral antibiotics for lung infections by directly delivering high drug concentrations to the infection site with minimal systemic drug absorption and exposure.
The global Inhaled Antibiotics Market is estimated to be valued at US$ 1,403.3 Mn in 2023 and is expected to exhibit a CAGR of 6.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics
Rising prevalence of chronic respiratory diseases is expected to drive the growth of the global inhaled antibiotics market demand during the forecast period. According to the Centers for Disease Control and Prevention, in the United States, over 30 million people are suffering from chronic lower respiratory diseases including COPD, asthma, and lung infections related to cystic fibrosis. Inhaled antibiotics are highly effective in treating lung infections caused by these chronic respiratory diseases as they directly deliver high concentration of drugs to the infection site in the lungs. Another driver for the market growth is increasing research and development activities by key players for development of novel and more effective inhaled antibiotic formulations. For instance, in March 2021, Insmed Incorporated announced that its phase 3 trial of Brexanolone for treatment of nontuberculous mycobacterial (NTM) lung infections met its primary endpoint. Such R&D efforts are expected to bring new product launches which will fuel the market growth over the forecast period.
Segment Analysis
The inhaled antibiotics market is segmented based on route of administration, drug class, indication, distribution channel and region. Among route of administration, the nebulizers segment is dominating and is expected to continue its dominance over the forecast period. Nebulizers are preferred mode of inhaled drug delivery due to advantages like precise and targeted drug delivery to lungs.
PEST Analysis
Political: Government regulations regarding clinical trials and approval process for new antibiotics affect the market. Strict guidelines ensure patient safety.
Economic: Increasing cases of respiratory infections and rising healthcare expenditure create high demand for innovative treatment options like inhaled antibiotics.
Social: Growing awareness about benefits of local drug delivery in lungs and advantages over oral and intravenous administration drive market growth.
Technological: Developments in inhaler device technology help improve drug delivery, efficacy and patient compliance. Digital adherence platforms also help patients effectively manage treatment.
Key Takeaways
The global Inhaled Antibiotics Market Growth is expected to witness high growth over the forecast period. The global inhaled antibiotics market is estimated to be valued at US$ 1,403.3 Mn in 2023 and is expected to exhibit a CAGR of 6.7% over the forecast period 2023 to 2030.
Regionally, North America is dominating currently due to technological advancements and availability of advanced healthcare facilities. Europe is also a major regional market.
Key players operating in the inhaled antibiotics market are Gilead Sciences, Aradigm, Lupin Ltd., Polyphor, Insmed Incorporated, Pharmaero, Savara Pharmaceuticals, Joincare Pharmaceutical Group, Teva Pharmaceuticals, Altan Pharmaceuticals, Raptor Pharmaceutical Corp., Cipla Limited, Maya Biotech Pvt. Ltd., Medisol Lifescience Pvt. Ltd., Nivon Specialties, Sentiss Pharma Pvt. Ltd., Ultratech India Limited, Midas Care Pharmaceuticals Pvt Ltd., Precept Pharma Ltd., Luckys Pharma, and Pharmaxis Ltd.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
